# Molson Coors Beverage Company (TAP) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/TAP/thesis · /stocks/TAP/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: TAP
step: 04
title: Financial Snapshot & Adversarial Research Sweep
retrieved: 2026-05-28
---

### Step 04 — Financial Snapshot

#### 1. Objective

Assess the quality of TAP's reported financials, identify accounting / one-time / impairment adjustments, and run the **Adversarial Research Sweep** for short-seller reports, investigations, lawsuits, and quality-of-earnings flags.

#### 2. Approach

Cross-referenced the cached XBRL summary [S1], reviewed FY2025 impairment disclosures [S2], scanned for litigation / short reports / investigations [S3][S4], and benchmarked GAAP-vs-underlying reconciliation against company-disclosed methodology [S2].

#### 3. Findings

##### Statement Quality — GAAP vs Underlying

The biggest single quality issue is the **FY2025 impairment package**: $3,645.7M Americas goodwill + $198.6M Staropramen brand + $75.3M Blue Run Spirits = $3,919.6M aggregate non-cash charges [S2]. All flow through GAAP operating income and to the GAAP net loss of $2,140M.

**Underlying basis** (company's preferred framing): excludes these impairments + restructuring charges + mark-to-market on commodity hedges + special items. Underlying EBITDA FY2025 ~$2.4B, underlying EPS ~$5.40 (consensus tracking estimate).

**Quality verdict:** GAAP loss is a true non-cash hit — equity book value reduced by ~$3.9B — but underlying cash-generative business is intact. For analytical purposes, use underlying figures for run-rate earnings power; use GAAP for full disclosure / equity-value-book-discipline check.

##### Cash Flow Conversion

| Year | OCF / Revenue | FCF / Revenue | OCF / EBITDA (underlying) | Comment |
|------|---------------|---------------|---------------------------|---------|
| 2025 | 16.0% | 9.6% | ~74% | Strong; little to flag |
| 2024 | 16.4% | 10.6% | ~77% | |
| 2023 | 17.8% | 12.0% | ~91% | Best year recent |
| 2022 | 14.0% | 7.9% | ~83% | |
| 2021 | 15.3% | 10.2% | ~68% | |

[S1]

Cash conversion is consistently in the 70–80%+ range of underlying EBITDA — high-quality, well-correlated with reported underlying earnings.

##### Working Capital Discipline

| YE | Receivables (% of revenue) | Inventory (% of revenue) | Payables (% of revenue) | Net working capital position |
|----|---------------------------|--------------------------|-------------------------|------------------------------|
| 2025 | 8.0% | 6.4% | 17.8% | Negative (favorable, ~3.4% benefit) |
| 2024 | 7.3% | 6.3% | 17.4% | Negative |
| 2023 | 7.5% | 6.9% | 18.2% | Negative |
| 2022 | 8.1% | 7.4% | 20.8% | Negative |

[S1]

TAP runs **negative working capital** (payables > receivables + inventory) — typical for CPG with distributor-led downstream financing. No red flags; payables-driven cash management is stable.

##### Capex Discipline

| Year | Capex ($M) | Capex / Revenue | Capex / D&A | Note |
|------|-----------|-----------------|-------------|------|
| 2025 | 717 | 6.4% | ~95% (D&A ~$760M) | Near maintenance |
| 2024 | 674 | 5.8% | ~90% | |
| 2023 | 672 | 5.7% | ~92% | |
| 2022 | 661 | 6.2% | ~95% | |

Capex roughly tracks D&A — no aggressive growth-investment cycle; mostly maintenance + can-line modernization. 2026 guide $650M (also near D&A).

##### Capital Structure Quality

- Long-term debt $3.81B (2025) — down from $6.06B in 2024 (refinancing / paydown / reclassification effect; some moved to current liabilities — current liab jumped to $5.31B from $3.05B reflecting near-term maturities)
- Net debt $5.4B (per company), 2.3x underlying EBITDA — below stated target of <2.5x [S2]
- Investment-grade credit ratings (BBB / Baa2 area)
- Manageable maturity ladder

##### Adversarial Research Sweep

**Short-seller reports:** No active major short-seller report on TAP identified [S3][S4]. Hindenburg, Muddy Waters, Citron, Spruce Point: no published TAP coverage in recent years.

**Litigation:** Standard product-liability tail risk + ordinary-course commercial disputes; no material outstanding litigation flagged in FY2025 10-K beyond routine.

**Regulatory investigations:** None disclosed [S2][S3].

**Quality-of-earnings flags:** 
1. **Goodwill impairment trigger:** The $3.65B Americas goodwill impairment in Q3 2025 was the principal QoE event. Triggered by softer-than-expected current-year results + lower long-term forecasts post-impairment-test [S2]. The market read this as honest reset of accounting carrying value vs. underlying operations.
2. **Blue Run Spirits impairment** ($75.3M, Q3 2025) — acquired 2023; growth target missed. Small relative to the package; signal: M&A discipline imperfect.
3. **Staropramen partial impairment** ($198.6M, Q3 2025) — softer CEE volumes; brand-equity reset.

**Cash-EPS bridge:** Underlying EPS ~$5.40 vs underlying FCF/share ~$5.40 (FCF $1,068M ÷ ~199M shares). They reconcile cleanly. No "earnings-without-cash" issue.

**Revenue recognition / channel stuffing:** Beer industry is volume-disclosed (HL shipped) — relatively hard to manipulate via revenue-recognition tricks. Distributor-channel inventory is monitored; TAP has not been flagged for channel-stuffing.

**Pension / OPEB:** Minor relative to size; no acute funding issue disclosed.

**Hedge accounting:** TAP uses commodity hedges (aluminum, barley, natural gas) and FX hedges. 2025 underlying-vs-GAAP reconciliation includes mark-to-market on non-designated hedges. Standard practice; not a red flag.

##### Adjusted Free Cash Flow Quality

Underlying FCF (using underlying definitions): roughly $1.0–1.1B annually 2024–2026. 2026 guide $1.1B ± 10% [S5]. This is the truest measure of capacity to fund dividend + buyback + de-leveraging.

#### 4. Risks & Counter-Evidence

- **Underlying-vs-GAAP gap is large in 2025** — management has flexibility in defining "underlying" — analyst should track quarter-by-quarter what adjustments are added and ensure they're truly non-recurring.
- **Brand impairment risk continues:** If US volumes decelerate further, ANOTHER goodwill impairment leg is possible (Americas goodwill now down to $1.95B vs $5.6B at YE2024; smaller cushion but not gone).
- **Tax rate:** 22–24% underlying ETR is consistent; no aggressive tax-planning red flag.

#### 5. Decision / What I'm doing differently

Use **underlying basis** for forward modeling. Apply a conservative haircut to underlying EBITDA forecast (10–15%) in the bear case to account for the possibility of further impairments or unfavorable adjustment reclassifications. GAAP results in 2025 are not predictive of run-rate earnings power.

#### 6. Open Questions

1. Will Q3 2026 (impairment-test annual cycle) trigger another non-cash charge? Watch volumes and pricing through H1 2026.
2. How does the $450M cost program show up in adjusted vs GAAP — will restructuring charges be excluded from underlying (the typical "add-back-then-take-credit" pattern)?

#### 7. Source Index

- [S1] `TAP_financials/xbrl/xbrl_summary.md`
- [S2] Molson Coors Q3 2025 10-Q and 8-K; FY2025 10-K
- [S3] Web search — short-seller report scan (no major TAP coverage from Hindenburg/Muddy Waters/Citron/Spruce Point in trailing 3 years)
- [S4] WSJ / FT / Reuters litigation databases — no material flagged
- [S5] Molson Coors 2026 guidance — Feb 18, 2026 8-K

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/TAP/fundamental

## Navigation

- Overview: /stocks/TAP
- Financials (this page): /stocks/TAP/financials
- Thesis: /stocks/TAP/thesis
- Investment Memo: /stocks/TAP/memo
- Coverage universe: /stocks